Even with three extremely efficient vaccines obtainable in abundance all through the nation, the delta variant of SARS-CoV-2 continues to trigger a lot of new infections, notably in states the place vaccination charges stay low. What’s extra, as faculties and companies reopen and the vacation season approaches, one other rise in infections could also be on the way in which.
There may be, nevertheless, some excellent news. Quite a few medicines, together with fledgling and repurposed medicine, are accessible. For hospitalized COVID-19 sufferers, these new remedies, together with supportive care advances – akin to inserting some sufferers on their stomachs in a “inclined place” – have been serving to deliver down mortality charges earlier than the Delta variant hit and are persevering with to enhance affected person outcomes at present.
As an infectious illnesses doctor and scientist, I’ve been working to search out new remedies for sufferers because the pandemic’s starting. Right here’s a have a look at a few of them, with one caveat: Whereas these medicines would possibly assist many sufferers, none substitute for the vaccine, which remains to be the very best protection in opposition to the virus.
John Moore by way of Getty Pictures
The correct drug on the proper time
COVID-19 has two major phases.
Within the early stage of the illness, the SARS-CoV-2 virus replicates within the physique; the virus itself causes sickness. Inside the first 10 days or so, the immune system eliminates the virus, however this course of could cause collateral harm.
A second section of the illness could kick in, which happens when the affected person has a disordered inflammatory response.
That’s why it’s vital to make use of the precise remedy drug on the proper time. As an illustration, an antiviral drug could assist a affected person with early and gentle signs. However it’s not helpful for somebody on a ventilator after weeks within the hospital.
Conversely, sufferers within the ICU would possibly profit from an inflammation-reducing drug, which might forestall harm to organs such because the kidney and lungs; this harm is named sepsis. However the identical drug used in the course of the viral section of illness would possibly hamper a affected person’s potential to struggle off COVID-19.
Three antiviral monoclonal antibody medicine approved to be used within the U.S. could preserve the virus from infecting new cells by concentrating on the SARS-CoV2 spike protein. For outpatients with early COVID-19, these medicine scale back the chance of hospitalization and demise. One in all them – REGEN-COV – could forestall high-risk sufferers from getting sick.
These antiviral medicine may additionally assist hospitalized sufferers whose our bodies are unable to make antibodies on their very own, both due to immune-compromising medicine or an impaired immune system from one other situation.
One examine that has not but been peer reviewed exhibits that hospitalized sufferers with no pure antiviral antibodies had a diminished danger of dying after receiving one among these medicine. However that remedy is often unavailable besides by a compassionate-use program. To get the medicine for a affected person, a doctor should ask each the drug producer and the FDA for approval.
One other drawback: Administering these antiviral medicine on a big scale is a problem. Well being care staff should give them shortly after the beginning of signs. The infusion or injection have to be in a monitored setting. Sufferers could discover it troublesome to rapidly entry the remedy.
Blended indicators on remdesivir
One in all these antiviral medicine, remdesivir, exhibits exercise within the lab in opposition to a broad vary of viruses, together with coronaviruses like SARS-CoV-2. It really works by blocking the virus from making extra copies of its genetic materials.
Two scientific trials carried out early within the pandemic present that remdesivir shortens restoration time for hospitalized COVID-19 sufferers. A newer trial prompt it diminished the chance of demise. However two extra trials, one carried out primarily in low- and middle-income nations by the World Well being Group and one other in Western Europe, didn’t present a transparent advantage of remdesivir in hospitalized sufferers.
The medical group has interpreted the conflicting information in numerous methods. Remdesivir obtained FDA approval to deal with COVID-19; each the Infectious Illnesses Society of America and the Nationwide Institutes of Well being advocate the drug for hospitalized sufferers. However the World Well being Group doesn’t, a minimum of exterior of a scientific trial.
John Moore by way of Getty Pictures
Steroids like dexamethasone can broadly suppress the immune system and, in flip, scale back irritation. For hospitalized sufferers, a routine of dexamethasone decreased the chance of demise, in line with a February 2021 examine revealed within the New England Journal of Drugs. The profit was biggest for sufferers requiring essentially the most respiratory assist. However in the identical examine, for sufferers without having for oxygen remedy, dexamethasone had no profit, and in reality may very well be dangerous.
Steroids are a blunt instrument for immune suppression; different anti-inflammatory medicine have an effect on the immune system extra exactly. Critically sick COVID-19 sufferers with irritation could have elevated ranges of the IL-6 cytokine, a molecule the immune system makes use of to coordinate a response. For these sufferers, each tocilizumab and sarilumab – two medicine that block cells from responding to IL-6 – could scale back irritation and reduce mortality when mixed with dexamethasone.
A category of medication referred to as JAK inhibitors – JAK being shorthand for a household of enzymes referred to as Janus kinases – can also modify the physique’s inflammatory response. They’re used for some autoimmune situations, together with rheumatoid arthritis, they usually block irritation attributable to IL-6.
Including baricitinib, a JAK inhibitor, to remdesivir helped hospitalized sufferers recuperate quicker than utilizing remdesivir alone. Baricitinib additionally diminished mortality in hospitalized sufferers handled with dexamethasone. And, with the sickest COVID-19 sufferers, it helped scale back irritation.
Of the medicine mentioned, in the mean time solely the antiviral monoclonal antibodies can be found for medical doctors to prescribe for sufferers who will not be within the hospital. There may be nonetheless a transparent want for different medicine to assist sufferers with early signs who will not be hospitalized. Older medicines that could be repurposed to deal with these sufferers embrace inhaled costicosteroids and fluvoxamine, an antidepressant.
A harmful pattern
As for the now-controversial drug ivermectin: Preliminary outcomes from one randomized, placebo-controlled trial didn’t present any profit for COVID-19 remedy. Two extra trials, additionally randomized and placebo-controlled, are underway.
For now, primarily based on present proof, ivermectin shouldn’t be used to deal with COVID-19 sufferers. When used incorrectly, this drug might trigger critical hurt. Ivermectin has been authorized for remedy of parasitic worms and head lice; however utilizing it off-label to deal with COVID-19 has resulted in overdoses and hospitalizations. Ivermectin toxicity could cause nausea, vomiting, diarrhea, low blood strain, confusion, seizures and demise.
The pressing seek for COVID-19 remedies has highlighted the necessity for high-quality science. Early on, restricted research led some to consider that hydroxychloroquine could be helpful for COVID-19. However over time, extra rigorous analysis confirmed the drug to don’t have any worth for COVID-19 remedy.
Randomized, placebo-controlled trials – wherein sufferers are randomly assigned to obtain both the take a look at drug or a placebo – signify medication’s gold customary. They assist medical doctors keep away from the numerous sources of bias that may lead us to conclude a drug is useful when it actually isn’t. Going ahead, it’s this type of analysis – and proof – that’s important to discovering new and efficient COVID-19 remedies.
[Get our best science, health and technology stories. Sign up for The Conversation’s science newsletter.]